The iQ Group Global Ltd., a life science organization, provides scientific intellectual property asset management services to multinational biopharma companies worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.20|
|52 Week High||AU$0.20|
|52 Week Low||AU$0.61|
|1 Month Change||-31.03%|
|3 Month Change||-33.33%|
|1 Year Change||-63.96%|
|3 Year Change||-50.00%|
|5 Year Change||-33.33%|
|Change since IPO||84.62%|
Recent News & Updates
|IQG||AU Life Sciences||AU Market|
Return vs Industry: IQG underperformed the Australian Life Sciences industry which returned -4.8% over the past year.
Return vs Market: IQG underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: Insufficient data to determine IQG's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine IQG's volatility change over the past year.
About the Company
The iQ Group Global Ltd., a life science organization, provides scientific intellectual property asset management services to multinational biopharma companies worldwide. The company offers services in the areas of corporatization and monetization of IP vested in compounds, devices, diagnostics, and technology platforms; data mining of patent portfolios; development of value-add patent strategies; identification and completion of portfolio acquisitions; pursuit of divestment and licensing opportunities; and provision of IP management services across various stages of the development life cycle. It also provides regulatory and market access services; contract sales and medical affairs services; and pharmacovigilance and specialized scientific services.
iQ Group Global Fundamentals Summary
|IQG fundamental statistics|
Is IQG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IQG income statement (TTM)|
|Cost of Revenue||AU$10.47m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.016|
|Net Profit Margin||20.16%|
How did IQG perform over the long term?See historical performance and comparison
Is iQ Group Global undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IQG (A$0.2) is trading below our estimate of fair value (A$0.78)
Significantly Below Fair Value: IQG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IQG is good value based on its PE Ratio (12.8x) compared to the Global Life Sciences industry average (46x).
PE vs Market: IQG is good value based on its PE Ratio (12.8x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IQG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IQG has negative assets, so we can't compare its PB Ratio to the AU Life Sciences industry average.
How is iQ Group Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iQ Group Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has iQ Group Global performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQG has a large one-off gain of A$30.0M impacting its June 30 2021 financial results.
Growing Profit Margin: IQG became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IQG has become profitable over the past 5 years, growing earnings by -7.2% per year.
Accelerating Growth: IQG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IQG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (59.8%).
Return on Equity
High ROE: IQG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is iQ Group Global's financial position?
Financial Position Analysis
Short Term Liabilities: IQG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IQG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IQG has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IQG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: IQG's debt is not well covered by operating cash flow (9.8%).
Interest Coverage: Insufficient data to determine if IQG's interest payments on its debt are well covered by EBIT.
What is iQ Group Global current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQG's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
George Syrmalis (55 yo)
Dr. George Syrmalis, M.D., Ph D., FACNP, MAAPP, has been Chief Executive Officer at FarmaForce Limited since November 24, 2015 and has been its Executive Director since November 24, 2015. He has been Chair...
CEO Compensation Analysis
Compensation vs Market: George's total compensation ($USD742.65K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
Experienced Board: IQG's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
The iQ Group Global Ltd.'s employee growth, exchange listings and data sources
- Name: The iQ Group Global Ltd.
- Ticker: IQG
- Exchange: NSX
- Founded: 2010
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$32.891m
- Shares outstanding: 164.46m
- Website: https://www.theiqgroupglobal.com
- The iQ Group Global Ltd.
- 85 Castlereagh Street
- Level 9
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:33|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.